Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial

Jorge E Cortes; Samer Khaled; Giovanni Martinelli; Alexander E Perl; Siddhartha Ganguly; Nigel Russell; Alwin Krämer; Hervé Dombret; Donna Hogge; Brian A Jonas; Anskar Yu-Hung Leung; Priyanka Mehta; Pau Montesinos; Markus Radsak; Simona Sica; Meena Arunachalam; Melissa Holmes; Ken Kobayashi; Ruth Namuyinga; Nanxiang Ge; Antoine Yver; Yufen Zhang; Mark J Levis

doi:10.1016/s1470-2045(19)30150-0

Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(19)30150-0 ◽

2019 ◽

Vol 20 (7) ◽

pp. 984-997 ◽

Cited By ~ 79

Author(s):

Jorge E Cortes ◽

Samer Khaled ◽

Giovanni Martinelli ◽

Alexander E Perl ◽

Siddhartha Ganguly ◽

...

Keyword(s):

Acute Myeloid Leukaemia ◽

Myeloid Leukaemia ◽

Salvage Chemotherapy ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Randomised Controlled ◽

Acute Myeloid

Download Full-text

Homoharringtonine-based induction regimens for patients with de-novo acute myeloid leukaemia: a multicentre, open-label, randomised, controlled phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(13)70152-9 ◽

2013 ◽

Vol 14 (7) ◽

pp. 599-608 ◽

Cited By ~ 55

Author(s):

Jie Jin ◽

Jian-Xiang Wang ◽

Fei-Fei Chen ◽

De-Pei Wu ◽

Jiong Hu ◽

...

Keyword(s):

Acute Myeloid Leukaemia ◽

Myeloid Leukaemia ◽

De Novo ◽

Open Label ◽

Phase 3 ◽

Randomised Controlled ◽

Acute Myeloid

Download Full-text

Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study

The Lancet ◽

10.1016/s0140-6736(12)60485-1 ◽

2012 ◽

Vol 379 (9825) ◽

pp. 1508-1516 ◽

Cited By ~ 489

Author(s):

Sylvie Castaigne ◽

Cécile Pautas ◽

Christine Terré ◽

Emmanuel Raffoux ◽

Dominique Bordessoule ◽

...

Keyword(s):

Acute Myeloid Leukaemia ◽

Myeloid Leukaemia ◽

De Novo ◽

Gemtuzumab Ozogamicin ◽

Adult Patients ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Acute Myeloid

Download Full-text

Faculty Opinions recommendation of Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717952822.793458289 ◽

2012 ◽

Author(s):

Georg Stüssi

Keyword(s):

Acute Myeloid Leukaemia ◽

Myeloid Leukaemia ◽

De Novo ◽

Gemtuzumab Ozogamicin ◽

Adult Patients ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Acute Myeloid

Download Full-text

Faculty Opinions recommendation of Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717958906.793462914 ◽

2012 ◽

Author(s):

Nelson Chao

Keyword(s):

Complete Remission ◽

Acute Myeloid Leukaemia ◽

Myeloid Leukaemia ◽

Cell Transplantation ◽

Reduced Intensity Conditioning ◽

Open Label ◽

Phase 3 ◽

First Complete Remission ◽

Reduced Intensity ◽

Acute Myeloid

Download Full-text

Two dosing regimens of tosedostat in elderly patients with relapsed or refractory acute myeloid leukaemia (OPAL): a randomised open-label phase 2 study

The Lancet Oncology ◽

10.1016/s1470-2045(13)70037-8 ◽

2013 ◽

Vol 14 (4) ◽

pp. 354-362 ◽

Cited By ~ 26

Author(s):

Jorge Cortes ◽

Eric Feldman ◽

Karen Yee ◽

David Rizzieri ◽

Anjali S Advani ◽

...

Keyword(s):

Elderly Patients ◽

Acute Myeloid Leukaemia ◽

Myeloid Leukaemia ◽

Phase 2 ◽

Open Label ◽

Phase 2 Study ◽

Open Label Phase ◽

Dosing Regimens ◽

Acute Myeloid

Download Full-text

Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study

The Lancet Oncology ◽

10.1016/s1470-2045(15)00201-6 ◽

2015 ◽

Vol 16 (9) ◽

pp. 1025-1036 ◽

Cited By ~ 85

Author(s):

Farhad Ravandi ◽

Ellen K Ritchie ◽

Hamid Sayar ◽

Jeffrey E Lancet ◽

Michael D Craig ◽

...

Keyword(s):

Acute Myeloid Leukaemia ◽

Myeloid Leukaemia ◽

Phase 3 ◽

Double Blind ◽

Randomised Controlled ◽

Acute Myeloid

Download Full-text

Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(20)30455-1 ◽

2020 ◽

Vol 21 (9) ◽

pp. 1201-1212 ◽

Cited By ~ 5

Author(s):

Li Xuan ◽

Yu Wang ◽

Fen Huang ◽

Zhiping Fan ◽

Yajing Xu ◽

...

Keyword(s):

Stem Cell ◽

Stem Cell Transplantation ◽

Acute Myeloid Leukaemia ◽

Myeloid Leukaemia ◽

Cell Transplantation ◽

Haematopoietic Stem Cell Transplantation ◽

Haematopoietic Stem Cell ◽

Open Label ◽

Phase 3 ◽

Acute Myeloid

Download Full-text

Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(15)00200-4 ◽

2015 ◽

Vol 16 (15) ◽

pp. 1525-1536 ◽

Cited By ~ 86

Author(s):

Alessandro Rambaldi ◽

Anna Grassi ◽

Arianna Masciulli ◽

Cristina Boschini ◽

Maria Caterina Micò ◽

...

Keyword(s):

Stem Cell ◽

Stem Cell Transplantation ◽

Acute Myeloid Leukaemia ◽

Myeloid Leukaemia ◽

Open Label ◽

Phase 3 ◽

Haemopoietic Stem Cell ◽

Preparative Regimen ◽

Haemopoietic Stem Cell Transplantation ◽

Acute Myeloid

Download Full-text

Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(12)70349-2 ◽

2012 ◽

Vol 13 (10) ◽

pp. 1035-1044 ◽

Cited By ~ 144

Author(s):

Martin Bornhäuser ◽

Joachim Kienast ◽

Rudolf Trenschel ◽

Andreas Burchert ◽

Ute Hegenbart ◽

...

Keyword(s):

Complete Remission ◽

Acute Myeloid Leukaemia ◽

Myeloid Leukaemia ◽

Cell Transplantation ◽

Reduced Intensity Conditioning ◽

Open Label ◽

Phase 3 ◽

First Complete Remission ◽

Reduced Intensity ◽

Acute Myeloid

Download Full-text

Faculty Opinions recommendation of Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717958906.793464270 ◽

2012 ◽

Author(s):

Anskar YH Leung

Keyword(s):

Complete Remission ◽

Acute Myeloid Leukaemia ◽

Myeloid Leukaemia ◽

Cell Transplantation ◽

Reduced Intensity Conditioning ◽

Open Label ◽

Phase 3 ◽

First Complete Remission ◽

Reduced Intensity ◽

Acute Myeloid

Download Full-text